Anthony A Portale1, Myles S Wolf2, Shari Messinger3, Farzana Perwad4, Harald Jüppner5, Bradley A Warady6, Susan L Furth7, Isidro B Salusky8. 1. Department of Pediatrics, University of California San Francisco, San Francisco, California; anthony.portale@ucsf.edu. 2. Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 3. Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida. 4. Department of Pediatrics, University of California San Francisco, San Francisco, California. 5. Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 6. Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri. 7. Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania; and. 8. Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
Abstract
BACKGROUND AND OBJECTIVES: Plasma fibroblast growth factor 23 (FGF23) concentrations increase early in the course of CKD in children. High FGF23 levels associate with progression of CKD in adults. Whether FGF23 predicts CKD progression in children is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We tested the hypothesis that high plasma FGF23 is an independent risk factor for CKD progression in 419 children, aged 1-16 years, enrolled in the Chronic Kidney Disease in Children (CKiD) cohort study. We measured plasma FGF23 concentrations at baseline and determined GFR annually using plasma disappearance of iohexol or the CKiD study estimating equation. We analyzed the association of baseline FGF23 with risk of progression to the composite end point, defined as start of dialysis or kidney transplantation or 50% decline from baseline GFR, adjusted for demographics, baseline GFR, proteinuria, other CKD-specific factors, and other mineral metabolites. RESULTS: At enrollment, median age was 11 years [interquartile range (IQR), 8-15], GFR was 44 ml/min per 1.73 m2 (IQR, 33-57), and FGF23 was 132 RU/ml (IQR, 88-200). During a median follow-up of 5.5 years (IQR, 3.5-6.6), 32.5% of children reached the progression end point. Higher FGF23 concentrations were independently associated with higher risk of the composite outcome (fully adjusted hazard ratio, 2.52 in the highest versus lowest FGF23 tertile; 95% confidence interval, 1.44 to 4.39, P=0.002; fully adjusted hazard ratio, 1.33 per doubling of FGF23; 95% confidence interval, 1.13 to 1.56, P=0.001). The time to progression was 40% shorter for participants in the highest compared with the lowest FGF23 tertile. In contrast, serum phosphorus, vitamin D metabolites, and parathyroid hormone did not consistently associate with progression in adjusted analyses. CONCLUSIONS: High plasma FGF23 is an independent risk factor for CKD progression in children.
BACKGROUND AND OBJECTIVES: Plasma fibroblast growth factor 23 (FGF23) concentrations increase early in the course of CKD in children. High FGF23 levels associate with progression of CKD in adults. Whether FGF23 predicts CKD progression in children is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We tested the hypothesis that high plasma FGF23 is an independent risk factor for CKD progression in 419 children, aged 1-16 years, enrolled in the Chronic Kidney Disease in Children (CKiD) cohort study. We measured plasma FGF23 concentrations at baseline and determined GFR annually using plasma disappearance of iohexol or the CKiD study estimating equation. We analyzed the association of baseline FGF23 with risk of progression to the composite end point, defined as start of dialysis or kidney transplantation or 50% decline from baseline GFR, adjusted for demographics, baseline GFR, proteinuria, other CKD-specific factors, and other mineral metabolites. RESULTS: At enrollment, median age was 11 years [interquartile range (IQR), 8-15], GFR was 44 ml/min per 1.73 m2 (IQR, 33-57), and FGF23 was 132 RU/ml (IQR, 88-200). During a median follow-up of 5.5 years (IQR, 3.5-6.6), 32.5% of children reached the progression end point. Higher FGF23 concentrations were independently associated with higher risk of the composite outcome (fully adjusted hazard ratio, 2.52 in the highest versus lowest FGF23 tertile; 95% confidence interval, 1.44 to 4.39, P=0.002; fully adjusted hazard ratio, 1.33 per doubling of FGF23; 95% confidence interval, 1.13 to 1.56, P=0.001). The time to progression was 40% shorter for participants in the highest compared with the lowest FGF23 tertile. In contrast, serum phosphorus, vitamin D metabolites, and parathyroid hormone did not consistently associate with progression in adjusted analyses. CONCLUSIONS: High plasma FGF23 is an independent risk factor for CKD progression in children.
Authors: Allan J Collins; Robert N Foley; Blanche Chavers; David Gilbertson; Charles Herzog; Areef Ishani; Kirsten Johansen; Bertram L Kasiske; Nancy Kutner; Jiannong Liu; Wendy St Peter; Haifeng Guo; Yan Hu; Allyson Kats; Shuling Li; Suying Li; Julia Maloney; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Bryn Thompson; Eric Weinhandl; Hui Xiong; Akeem Yusuf; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frank Daniels; James Ebben; Eric Frazier; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Delaney Berrini; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2014-01 Impact factor: 8.860
Authors: Inga Soveri; Ulla B Berg; Jonas Björk; Carl-Gustaf Elinder; Anders Grubb; Ingegerd Mejare; Gunnar Sterner; Sten-Erik Bäck Journal: Am J Kidney Dis Date: 2014-05-17 Impact factor: 8.860
Authors: Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress Journal: Lancet Date: 2010-11-06 Impact factor: 79.321
Authors: Katherine Wesseling-Perry; Eileen W Tsai; Robert B Ettenger; Harald Jüppner; Isidro B Salusky Journal: Nephrol Dial Transplant Date: 2011-03-25 Impact factor: 5.992
Authors: Bradley A Warady; Alison G Abraham; George J Schwartz; Craig S Wong; Alvaro Muñoz; Aisha Betoko; Mark Mitsnefes; Frederick Kaskel; Larry A Greenbaum; Robert H Mak; Joseph Flynn; Marva M Moxey-Mims; Susan Furth Journal: Am J Kidney Dis Date: 2015-03-19 Impact factor: 8.860
Authors: Susan L Furth; Alison G Abraham; Judith Jerry-Fluker; George J Schwartz; Mark Benfield; Frederick Kaskel; Craig Wong; Robert H Mak; Marva Moxey-Mims; Bradley A Warady Journal: Clin J Am Soc Nephrol Date: 2011-08-12 Impact factor: 8.237
Authors: Michel Chonchol; Berenice Gitomer; Tamara Isakova; Xuan Cai; Isidro Salusky; Renata Pereira; Kaleab Abebe; Vicente Torres; Theodor I Steinman; Jared J Grantham; Arlene B Chapman; Robert W Schrier; Myles Wolf Journal: Clin J Am Soc Nephrol Date: 2017-07-13 Impact factor: 8.237
Authors: Mark R Hanudel; Michele F Eisenga; Maxime Rappaport; Kristine Chua; Bo Qiao; Grace Jung; Victoria Gabayan; Barbara Gales; Georgina Ramos; Maarten A de Jong; Jelmer J van Zanden; Martin H de Borst; Stephan J L Bakker; Elizabeta Nemeth; Isidro B Salusky; Carlo A J M Gaillard; Tomas Ganz Journal: Nephrol Dial Transplant Date: 2019-12-01 Impact factor: 5.992
Authors: Mark M Mitsnefes; Aisha Betoko; Michael F Schneider; Isidro B Salusky; Myles Selig Wolf; Harald Jüppner; Bradley A Warady; Susan L Furth; Anthony A Portale Journal: Clin J Am Soc Nephrol Date: 2017-10-12 Impact factor: 8.237
Authors: Rupal Mehta; Xuan Cai; Jungwha Lee; Dawei Xie; Xue Wang; Julia Scialla; Amanda H Anderson; Jon Taliercio; Mirela Dobre; Jing Chen; Michael Fischer; Mary Leonard; James Lash; Chi-Yuan Hsu; Ian H de Boer; Harold I Feldman; Myles Wolf; Tamara Isakova Journal: Am J Kidney Dis Date: 2019-12-19 Impact factor: 8.860